Background: It often takes more than 10 years and costs more than one billion dollars to develop a new drug for a disease and bring it to the market. Drug repositioning can significantly reduce costs and times in drug development. Recently, computational drug repositioning attracted a considerable amount of attention among researchers, and a plethora of computational drug repositioning methods have been proposed.
Background
Drug research and development is a time-consuming, expensive and complicated process.
Previous research reported that it often takes 10-15 years and 0.8-1.5 billion dollars to develop a new drug and bring it to the market [1] . Although such a huge amount of time and money is expanding in this industry, the number of new FDA-approved drugs annually remains low. So, in light of these challenges, finding a new use for an existing drug, which is known as drug repositioning or drug repurposing, has been proposed as a solution for such problem. The goal of drug repositioning is to identify new indications for existing drugs. The result of using such approaches can reduce the overall cost of commercialization, and also eliminate the delay between drug discovery and availability. In comparison to the traditional drug repositioning which relies on clinical discoveries, computational drug repositioning methods can simplify the drug development timeline [2] [3] [4] [5] [6] .
In recent years, different approaches were exploited for repurposing drugs, including network, text mining, machine learning and semantic inference based approaches. Recently, networkbased approach attracted more attention and was widely used in computational drug repositioning due to the capability of using ever-increasing large scale biological datasets such as genetic, pharmacogenomics, clinical and chemical data [2, 5, [7] [8] [9] [10] [11] [12] [13] [14] .
In this study, we have proposed a network-based approach for drug repositioning. Our method, namely RepCOOL, integrated various heterogeneous biological networks to obtain new drug-disease associations. The proposed method showed a satisfactory performance in detecting drug-disease associations via stringent assessment procedures. Eventually, four new drugs were suggested for breast cancer. 
Method:

Data sources
We have constructed nine different drug-disease association networks using six primary networks that were constructed based on the publicly available database (Table 1) . These six network can be categorized into four different groups according to their types of nodes: druggene interaction network (DRGN), disease-gene interaction network (DIGN), protein-protein interaction network (PPIN) and gene co-expression network (GCN).
Drug-gene interaction network
We used DrugBank [15] database to construct DRGN network. DrugBank provides comprehensive information about approved and investigational drugs, including UMLS-mapped approved indications. This network includes 3,509 interactions between 1,497 drugs and 673 genes.
Extracting Primary Data
Constructing Drug-Disease Networks 
Disease-gene interaction network
We used three databases for constructing three different disease-gene interaction networks ( 
Protein-protein interaction network
We extracted protein-protein interaction (PPI) information from IntAct database [19] . IntAct provides a freely available database system and analysis tools for molecular interaction data.
This network has 16,523 proteins and 143,738 protein-protein interactions.
Gene co-expression network
We have constructed gene co-expression network (GCN) using COXPRESdb database [20] . This database measured the similarity of gene expression patterns during several conditions such as disease states tissue types. COXPRESdb includes co-expression relationships for multiple animal species and is freely available on http://coxpresdb.jp/. The obtained GCN includes 12,485 interactions and 24,442 genes. 
Reconstructing new drug-disease networks via merging heterogeneous networks
We have reconstructed nine new drug-disease networks using six primary networks. Figure 2 shows a schematic of the reconstruction of these networks. These nine networks have more than 9,400,000 drug-disease associations in total. Table 2 shows more details about these new drugdisease networks. One drug-disease interaction may be generated more than once in each network merging. So, the number of occurrences of a drug-disease interaction is considered as the weight of that interaction. 
Drug-disease association prediction
Encoding drug-disease networks as feature vectors
For each drug-disease pair, weights of its corresponding interaction in the reconstructed drugdisease networks were considered as features. Therefore, each drug-disease pair was encoded as a 9-dimentional feature vector.
Machine learning methods
We have used five different classifiers including naïve Bayes (NB), random forest (RF), logistic regression (LR), decision tree (DT) and support vector machine (SVM). The implementations of these classifiers in Weka [21] software package was used for drug-disease association prediction. Weka is a java based machine learning workbench that was developed for machine learning tasks. Also, we used 10-fold cross validation for evaluating the predicted drugdisease associations.
For evaluating the performance of RepCOOL, we used 4 different measures (Table 3) We also, used area under ROC curve (AUC) as another measure for assessing the proposed method. 
Benchmark dataset:
We used PREDICT [22] , which is a well-known benchmark dataset in drug repositioning, to assess the strength of the proposed drug repositioning method. PREDICT dataset includes 1,834
interactions between 526 FDA approved drugs and 314 diseases.
Results and discussion
The harmonic mean of sensitivity and specificity
Performance evaluation of the proposed method Figure 3 . shows the performance of five classifiers on the PREDICT dataset in a 10-fold cross validation experiment. As it is evident, decision tree is the most sensitive classifier in detecting true drug-disease associations but random forest has the best performance in term of ROC. For all the classifiers recall (sensitivity) is in a satisfactory range, which shows the ability to detect true drug-disease associations. However, precision is relatively low for almost all classifiers, which can be a result of some true drug-disease associations that has not been discovered or reported yet. 
Comparison with the other methods:
Nearly all of the previously published studies only reported their AUC. As it is shown in figure 4 the highest AUC of the five classifiers is 0.83, which shows better performance than HGBI [23] , LDB [24] , TL-HGB [25] and Drug Net [24] methods on PREDICT dataset. 
New repurposed drugs for breast cancer
Information contained in RepoDB [26] was exploited to obtain a list of new repurposed drugs for breast cancer. RepoDB includes a gold standard set of drug repositioning which have been failed or succeeded. The RepoDB dataset contains 6,677 approved, 2,754 terminated, 483 suspended and 648 withdrawn drug-disease interactions. Withdrawn and suspended drug-disease associations have annotation phase between phase 0 and phase 3. Therefore, these two types of drug-disease pairs have more potential to suggest a valid new drug repositioning rather than a random pair. Considering this fact, we have trained the five classifiers using the approved and terminated data. Figure 5 shows the training performance of the classifiers. Then, the best performing classifier, according to the approved and terminated data, was used to predict new drugs for breast cancer. The most sensitive classifier, which was random forest (it detected 2,283 true drug-disease interactions out of 2,292), was used to do this end. Using this classifier, four new drugs have been repurposed for breast cancer stage II. Table.3 shows the chemical structures for these drugs and a brief description for each one.
B on
Analyzing the structural similarity between the four new repurposed drugs and previously FDA-approved drugs for breast cancer:
We also did a structural similarity analysis between the repurposed drugs and 10 FDAapproved drugs for breast cancer including 5-FU, Abemaciclib, Verzeino, Taxotere (docetaxol), danazol, Pamidronate Disodium, Trastuzumab, Tamoxifen, Doxorubicin, Paclitaxel, Capecitabine, Dutasteride, Olaparib, Afinitor. Figure 6 shows the results of the structural similarity analysis. Structural similarity was computed based on 3,014 structural features that was extracted using Dragon tool [27] . 
MTT Assay
An MTT assay was also done to assess the effectiveness of the repurposed drugs ( figure 7 ). According to our limitations we did the MTT assay only for tamoxifen. Human cell line BT474 was cultured in 
Conclusion
In this study a network based approach was exploited for drug repositioning using heterogeneous biological and chemical information. Results show the strength of the proposed method in detecting true drug-disease relationships. RepCOOL suggested four new drugs for breast cancer stage II namely Doxorubicin, Paclitaxel, Trastuzumab and Tamoxifen. Structural analysis showed high structural similarity of this four drugs to the current FDA-approved drugs for breast cancer stage II. In addition, we did an MTT assay for one of the suggested drugs (Tomoxifen), which had IC 50 of 32.13 µM. 
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